Phase 3 Clinical Study for the Treatment of Cold Sore

Summary

To demonstrate the efficacy of a single dose of acyclovir Lauriad® 50mg muco-adhesive buccal tablet versus a single dose of matching placebo on the primary vesicular lesion of cold sore.

Timeline

Start

2007-05

Primary completion

2008-11

Completion

2009-08

Outcome

Met primary endpoint

registry MEDIAN Acyclovir Lauriad Group: 7.00 (95% Confidence Interval 0.18) Days NCT00769314 ↗

registry analysis (superiority or other test); Acyclovir Lauriad Group vs Placebo Group; p = 0.015; Log Rank NCT00769314 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Acyclovir	Small molecule	50 mg	Other

Indications